Special Issue "Antibody-Based Therapeutics for Treating Cancer"

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: 31 December 2018

Special Issue Editors

Guest Editor
Prof. Daruka Mahadevan

Professor of Medicine,
Director, New Therapeutics Program,
Co-Chair, Therapeutic Development Program,
Endowed Chair, Margaret E. and Fenton L. Maynard Excellence in Breast Cancer Research,
University of Arizona Cancer Center, Room 1905,
1515 N. Campbell Avenue,
Tucson, AZ 85724, USA
Website | E-Mail
Interests: Antibody-Based Therapeutics for Treating Cancer
Guest Editor
Dr. Faiz Anwer

Associate Professor of Medicine,
University of Arizona Cancer Center, Room 1905,
1515 N. Campbell Avenue,
Tucson, AZ 85724, USA
E-Mail
Interests: Anti-Cancer Therapies

Special Issue Information

Dear Colleagues,

Therapeutic monoclonal antibodies (Mabs) targeting oncogenic cell surface receptors on tumor cells and cells of the tumor microenvironment are an important therapeutic modality in both solid and hematologic malignancies. These targets include secreted ligands (e.g., VEGF and HGH), their receptors (e.g., HER1, VEGFR2, CD20), immune checkpoints and their ligands (e.g., PD-1 and PD-L1) immune activators (e.g. CD40, OX40) and antibody drug conjugates (e.g. TDM-1). The ability to genetically engineer the structure/functions of Mabs provides novel ways to improve their efficacy and safety. Multi-omics technologies and immune monitoring have allowed serial sampling of tumor and blood/serum to better understand response and resistance to therapy in addition to deciphering of complex signaling networks that drive oncogenic resistance.

This Special Issue of Antibodies focuses on disease specific USFDA approval of therapeutic Mabs for solid and hematologic malignancies. In addition, novel immune checkpoint inhibiting and activating Mabs for disease specific and tumor agnostic indications will also be discussed. In addition, safety, tolerability and side effects will also be reviewed. Finally, we also discuss promising novel Mabs in early- and late-phase clinical trials, likely to impact disease elimination and improve survival.

Prof. Daruka Mahadevan
Dr. Faiz Anwer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 350 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Anti-Cancer Therapeutic Antibodies
  • Immune checkpoint Antibodies
  • Antibody Drug Conjugates
  • Combination Therapies

Published Papers

This special issue is now open for submission.
Back to Top